Showing results (221-230 of 261) with videos related to

Sort By:
Pageof 27
Cancer Medicine|August 20, 2020
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinomaYusuke Okuma, Yasushi Goto, Fumiyoshi Ohyanagi, et al.
Structure (London, England : 1993)|September 10, 2010
Structural insight into the zinc finger CW domain as a histone modification readerFahu He, Takashi Umehara, Kohei Saito, et al.
The Journal of Biological Chemistry|April 6, 2013
Aberrant assembly of RNA recognition motif 1 links to pathogenic conversion of TAR DNA-binding protein of 43 kDa (TDP-43)Akemi Shodai, Toshifumi Morimura, Akemi Ido, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint InhibitorsFyza Y Shaikh, James R White, Joell J Gills, et al.
European Journal of Clinical Pharmacology|January 18, 2022
Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitantHideyuki Hibino, Naomi Sakiyama, Yoshinori Makino, et al.
Cancer Science|October 26, 2022
Nivolumab-induced radiation recall pneumonitis in non-small-cell lung cancer patients with thoracic radiation therapyShoko Noda-Narita, Tomoyuki Naito, Hibiki Udagawa, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2020
Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapyYusuke Okuma, Ryo Ko, Takehito Shukuya, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 9, 2025
Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)Taiki Hakozaki, Kentaro Tanaka, Yoshimasa Shiraishi, et al.
Translational Lung Cancer Research|September 27, 2019
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patientsAkihiro Yoshimura, Tadaaki Yamada, Yusuke Okuma, et al.
Pageof 27